Answers are grounded in this paper and cite their sources.
// Santanu Maji 1, 2, * , Sabindra K Samal 1, 2, * , Laxmipriya Pattanaik 1 , Swagatika Panda 3 , Bridget A. Quinn 4 , Swadesh K. Das 4, 5, 6 , Devanand Sarkar 4, 5, 6 , Maurizio Pellecchia 7 , Paul B. Fisher 4, 5, 6 , Rupesh Dash 1 1 Institute of Life Sciences, Bhubaneswar, Odisha, India 2 Manipal University, Karnataka, India 3 Department of Oral Pathology & Microbiology, Institute of Dental Sciences, ‘Siksha O Anusandhan’ University, Bhubaneswar, Odisha, India 4 Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA 5 VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA 6 VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, USA 7 Sanford-Burnham Medical Research Institute, La Jolla, California, USA * These authors have contributed equally to this work Correspondence to: Rupesh Dash, e-mail: rupesh.dash@gmail.com Keywords: Mcl-1, OSCC, mitophagy, sabutoclax, 4-NQO Received: January 04, 2015 Accepted: April 30, 2015 Published: May 14, 2015 ABSTRACT Oral and oropharyngeal cancers are the sixth most common cancers worldwide. Despite intensive investigation, oral squamous cell carcinomas (OSCC) represent a clinical challenge resulting in significant morbidity and mortality. Resistance to cell death is common in OSCC and is often mediated by the Bcl-2 family proteins. Among all anti-apoptotic Bcl-2 family members, Mcl-1 functions as a major survival factor, particularly in solid cancers. Despite the confirmed importance of Mcl-1 in several neoplasms, the role of Mcl-1 in OSCC survival has yet to be explored. In this study, we found that knocking down Mcl-1 sensitized OSCC cells to ABT-737, which binds to Bcl-2/Bcl-x L but not Mcl-1. We report for the first time that a BH3 mimetic, Sabutoclax, which functions as an inhibitor of all anti-apoptotic Bcl-2 proteins, induced cancer-specific cell death in an Mcl-1-dependent manner through both apoptosis and toxic mitophagy. In vivo studies demonstrated that Sabutoclax alone decreased tumor growth in a carcinogen-induced tongue OSCC mouse model. In a combination regimen, Sabutoclax and COX-2 inhibitor, Celecoxib, synergistically inhibited the growth of OSCC in vitro and also significantly reduced OSCC tumor growth in vivo . Overall, these results identify Mcl-1 as a therapeutic prospective target in OSCC.
No takes yet. Share an insight, caveat, or question.
Maji et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: